Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of MT921 in Healthy Subjects
NCT03905291Phase 1Completed
- Sponsor
- Medytox Inc.
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Nuviju in submental fat (4 arms), sponsored by Medytox Inc. Primary endpoints: Maximum Concentration at 24 hours, Area Under the Curve 0-24h and 2 more. Started Jul 2018; status: completed.
02
Drugs
Nuviju
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT03905291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905291.